Outlook Therapeutics · ONS-5010 · Aug 2025
What did the FDA's August 2025 letter object to?
One deficiency, as Outlook reported it: a lack of substantial evidence of effectiveness, because NORSE EIGHT did not meet its primary endpoint. The FDA recommended confirmatory evidence and noted that NORSE TWO had met its endpoint.
EphemerisX Research · Published · 5 source documents · 1 min read
Short answer
According to Outlook's press release of August 28, 2025, the letter had a single deficiency, a lack of substantial evidence of effectiveness: NORSE EIGHT did not meet its primary endpoint, and the FDA recommended that confirmatory evidence of efficacy be submitted. The letter's own statement of that deficiency is on a page without a text layer.
What the evidence shows
Outlook's 10-K calls it a second CRL
10-K · Dec 19, 2025. The press release: The CRL included only one deficiency, for a lack of substantial evidence of effectiveness
8-K · Sep 2, 2025. In the CRL, the FDA advised that, because ONS-5010 did not meet the primary efficacy endpoint in NORSE EIGHT, it is recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010
8-K · Sep 2, 2025. Additionally, the FDA reiterated that NORSE TWO met its primary endpoint for effectiveness
8-K · Sep 2, 2025.
The trial result behind it was first reported in November 2024: ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA)
8-K · Nov 27, 2024. The difference between the arms was -2.257 BCVA letters with a 95% confidence interval of (-4.044, -0.470) while the lower bound of the pre-specified non-inferiority margin in the SPA was -3.5
8-K · Nov 27, 2024.
Two weeks before the letter, the company had said it had preparations underway in advance of potential U.S. FDA approval later this month
8-K · Aug 14, 2025. After it, the CEO is quoted: It is important to also note that the CRL identified no other outstanding deficiencies in our BLA
8-K · Sep 2, 2025.
The pages of the letter that have a text layer give instructions on labeling, the proposed name, a safety update and resubmission: A resubmission must fully address all the deficiencies listed in this letter
FDA · Aug 27, 2025 · p. 3, and the proposed brand name was found conditionally acceptable pending approval of the application in the current review cycle
FDA · Aug 27, 2025 · p. 2. The signature page is dated 08/27/2025
FDA · Aug 27, 2025 · p. 5.
The first page of each FDA letter, which states the deficiency, has no text layer in the published PDF and is not quoted here.
Follow the thread
- Was the FDA's August 2025 letter its first Complete Response Letter on ONS-5010?“Second CRL”: only one deficiency
- What changed between the FDA's August and December 2025 letters?The August letter's reason, as reported
- How did Outlook's description of NORSE EIGHT change?NORSE EIGHT misses its week-8 endpoint
- Why do Outlook's filings give different dates for the FDA's letters?Signed 08/27/2025
This investigation connects to
- What happens after a second FDA Complete Response Letter?Cross-investigation · Divergent outcome · with Aldeyra Therapeutics, CorMedix, Replimune, Verrica Pharmaceuticals
- When is one trial enough? How the FDA weighed the evidence in three programsCross-investigation · Comparable evidence · with Aldeyra Therapeutics, Replimune
The documents, by date
The passages quoted
Outlook Therapeutics Form 8-K, filed November 27, 2024
ONS-5010 did not meet the pre-specified non-inferiority endpoint at week 8 set forth in the special protocol assessment (SPA) with the U.S. Food and Drug Administration (FDA).Open at the source →
Outlook Therapeutics Form 8-K, filed November 27, 2024
The difference in the means between the ONS-5010 and ranibizumab in the NORSE EIGHT trial was -2.257 BCVA letters with a 95% confidence interval of (-4.044, -0.470) while the lower bound of the pre-specified non-inferiority margin in the SPA was -3.5 at a 95% confidence interval; the hypothesis of noninferiority was not met (p>0.025).Open at the source →
Outlook Therapeutics Form 8-K, filed August 14, 2025
We continue to execute on our commercial pathway forward and have preparations underway in advance of potential U.S. FDA approval later this month.”Open at the source →
FDA Complete Response Letter, August 27, 2025 · page 2
This name was found conditionally acceptable pending approval of the application in the current review cycle. Please resubmit the proposed proprietary name when you respond to all the application deficiencies that have been identified in this letter.Open at the source →
FDA Complete Response Letter, August 27, 2025 · page 3
A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with "RESUBMISSION" in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.Open at the source →
Outlook Therapeutics Form 8-K, filed September 2, 2025
It is important to also note that the CRL identified no other outstanding deficiencies in our BLA.”Open at the source →
Outlook Therapeutics Form 8-K, filed September 2, 2025
The CRL included only one deficiency, for a lack of substantial evidence of effectiveness. In the CRL, the FDA advised that, because ONS-5010 did not meet the primary efficacy endpoint in NORSE EIGHT, it is recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010. Additionally, the FDA reiterated that NORSE TWO met its primary endpoint for effectiveness.Open at the source →
Outlook Therapeutics Form 10-K, filed December 19, 2025
On August 27, 2025, we received a second CRL from the FDA. This CRL included only one deficiency, for a lack of substantial evidence of effectiveness. In the CRL, the FDA advised that, because ONS-5010 did not meet the primary efficacy endpoint in NORSE EIGHT, it is recommended that confirmatory evidence of efficacy be submitted to support the application for ONS-5010. Additionally, the FDA reiterated that NORSE TWO met its primary endpoint for effectiveness.Open at the source →